MDWD Logo.jpg
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 08h00 HE | MediWound Ltd.
YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief...
MDWD Logo.jpg
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
15 août 2024 16h15 HE | MediWound Ltd.
YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and...
MDWD Logo.jpg
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
14 août 2024 07h00 HE | MediWound Ltd.
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable...
MDWD Logo.jpg
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
05 août 2024 07h30 HE | MediWound Ltd.
YAVNE, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of...
MDWD Logo.jpg
MediWound to Report Second Quarter 2024 Financial Results
02 août 2024 08h00 HE | MediWound Ltd.
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MDWD Logo.jpg
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
29 juil. 2024 08h00 HE | MediWound Ltd.
Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 ...
MDWD Logo.jpg
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
16 juil. 2024 07h30 HE | MediWound Ltd.
Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule ...
MDWD Logo.jpg
MediWound Announces $25 Million Strategic Private Placement Financing
15 juil. 2024 07h00 HE | MediWound Ltd.
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a...
MDWD Logo.jpg
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
29 mai 2024 07h00 HE | MediWound Ltd.
 NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H...
MDWD Logo.jpg
MediWound to Report First Quarter 2024 Financial Results
22 mai 2024 08h00 HE | MediWound Ltd.
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...